Lyra Therapeutics, Inc. kajeno e phatlalalitse hore mokuli oa pele o ile a phekoloa Karolong ea 1 / karolo e sa reroang ea teko ea meriana ea Phase 2 BEACON ea LYR-220 ho bakuli ba baholo ba nang le rhinosinusitis e sa foleng (CRS) ba kileng ba etsoa opereishene ea sinus pele. LYR-220 e etselitsoe ka ho khetheha ho fana ka likhoeli tse tšeletseng tsa meriana e tsoelang pele e thibelang ho ruruha ka mokhoa o laoloang le o tsitsitseng ho litemaneng tsa sinonasal bakeng sa bakuli ba limilione ba CRS ba tsoelang pele ho hloka phekolo ho sa tsotellehe ho buuoa pele. Liphetho tsa maemo a holimo ho tsoa Karolong ea 1 ea Mokhahlelo oa 2 oa teko ea BEACON li lebelletsoe bofelong ba selemo.
"Re na le mekhoa ea phekolo e fokolang 'me hangata e sa sebetseng ho fokotsa matšoao a phehellang, a boima ho bakuli ba CRS ba kileng ba buuoa," ho boletse Anders Cervin, MD, PhD, Molula-setulo oa Otolaryngology Setsing sa Lipatlisiso tsa Clinical, Royal Brisbane & Women's Hospital. Khampase, Herston, Queensland, Australia, le Mofuputsi e Moholo thutong ea BEACON. "LYR-220 e ka emela tsoelo-pele e molemo ea tlhokomelo bakeng sa bakuli bana ba sa fumaneheng, bao bongata ba bona ba se nang mekhoa e amohelehang ea phekolo ea meriana."
Teko ea Phase 2 BEACON ke thuto e laoloang ea sehlopha se ts'oanang ho lekola polokeho, mamello, pharmacokinetics, le katleho ho bapisa meralo e 'meli ea matrix ea LYR-220 (7500µg MF) ho laola, nakong ea libeke tse 24, ho batho ba baholo ba nang le matšoao a 70. Batho ba CRS ba kileng ba etsoa opereishene ea pele ea sinus. Karolo ea 1 ke boithuto bo sa reroang, bo bulehileng bo hlahlobang monyetla oa ho beoa ho ntlafatsa ts'ebetso, ha Karolo ea 2 e tla ba e foufalitsoeng ke mokuli, 1: 1: 1 tlhahlobo e sa reroang ea meralo e 'meli khahlano le taolo ea bolotsana. Khampani e lebelletse ho phethela ho ingolisa bakeng sa teko e felletseng ea Mohato oa 2 BEACON ho elella bofelong ba selemo.
"Sena se emela ketsahalo ea bohlokoahali ho Lyra ha re ntse re ntšetsa pele mokhethoa oa rona oa bobeli oa sehlahisoa sa CRS ho nts'etsopele ea morao-rao, e re behang monyetla oa ho ba ba pele ba ho fana ka tharollo bakeng sa bongata bo felletseng ba bakuli ba CRS ba tšoaroang ke lingaka tsa ENT," ho boletse Maria Palasis, PhD. , Mopresidente le Ofisiri e ka Sehloohong ea Phethahatso ea Lyra Therapeutics. "Re labalabela ho ntšetsa pele LYR-220 ka tleliniki le ho sebelisa tsela ea LYR-210, kalafo ea rona ea lipatlisiso bakeng sa bakuli ba CRS ba nang le anatomy ea ho buuoa, eo hajoale e leng tekong ea bohlokoa ea Mokhahlelo oa 3 (ENLIGHTEN I), bakeng sa litlatsetso tsa taolo tsa nako e tlang. ”
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- The Phase 2 BEACON trial is a controlled parallel-group study to evaluate safety, tolerability, pharmacokinetics, and efficacy comparing two designs of the LYR-220 (7500µg MF) matrix to control, over a 24-week period, in approximately 70 symptomatic adult CRS subjects who have had a prior bilateral sinus surgery.
- today announced that the first patient was treated in the Part 1/non-randomized portion of the Phase 2 BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) who have had a prior sinus surgery.
- LYR-220 is specifically designed to deliver six months of continuous anti-inflammatory medication in a controlled and consistent fashion to the sinonasal passages for the millions of CRS patients that continue to require treatment despite a prior surgery.
